v3.26.1
Research Collaboration and License Agreements - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Millions
 1 Months Ended 3 Months Ended 4 Months Ended 12 Months Ended
Nov. 30, 2017
Mar. 31, 2026
Mar. 31, 2025
Dec. 31, 2015
Dec. 31, 2018
Dec. 31, 2025
Dec. 31, 2024
Jun. 18, 2024
May 31, 2024
Jul. 31, 2021
Dec. 31, 2017
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved   $ 3.2 $ 4.5     $ 3.5 $ 7.8        
Collaboration contract asset and other assets   3.5       3.8          
Contract with customer, liability   190.0 259.4     $ 205.6 $ 448.2        
Revenue   15.6 188.8                
Operating expenses   (79.4) (117.4)                
Net loss   $ (57.6) $ 82.9                
Basic (in dollars per share)   $ (0.90) $ 1.14                
Diluted (in dollars per share)   $ (0.90) $ 1.14                
Removal of Combination Trials                      
Research Collaboration And License Agreements [Line Items]                      
Revenue     $ 150.2                
Operating expenses     (2.6)                
Net loss     $ (147.6)                
Basic (in dollars per share)     $ 2.04                
Diluted (in dollars per share)     $ 2.03                
Updated Research Timelines                      
Research Collaboration And License Agreements [Line Items]                      
Revenue     $ (2.5)                
Net loss     $ (2.5)                
Basic (in dollars per share)     $ 0.03                
Diluted (in dollars per share)     $ 0.03                
Pfizer, Inc.                      
Research Collaboration And License Agreements [Line Items]                      
Payments received         $ 28.0            
Revenue   $ 1.2 $ (1.1)                
Pfizer, Inc. | Collaboration Agreement                      
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved                   $ 650.0  
Collaboration agreement direct and incremental costs incurred   12.9                  
Collaboration contract asset and other assets   12.9                  
Pfizer, Inc. | Regulatory and Sales-Based Milestones | Maximum                      
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved                   1,400.0  
Pfizer, Inc. | Regulatory Milestone Related to Marketing Approvals                      
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved                   400.0  
Pfizer, Inc. | Sales-Based Milestones                      
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved                   $ 1,000.0  
Pfizer, Inc. | Option Payments To License Agreement | Maximum                      
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved   3.8                  
Pfizer, Inc. | Development Milestone Payments                      
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved               $ 50.0      
Pfizer, Inc. | Development Milestone Payments | Maximum                      
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved                     $ 225.0
Pfizer, Inc. | Sales Based Milestone Payments | Maximum                      
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved                     $ 550.0
Novartis Pharma AG | License                      
Research Collaboration And License Agreements [Line Items]                      
Contract with customer, liability                 $ 150.0    
Contingent payments                 $ 1,010.0    
Genentech                      
Research Collaboration And License Agreements [Line Items]                      
Payments received $ 34.5     $ 11.0              
Genentech | Regulatory Milestone Related to Marketing Approvals                      
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved   52.5                  
Genentech | Development Milestone Payments | Maximum                      
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved   44.0                  
Genentech | Commercial Milestones                      
Research Collaboration And License Agreements [Line Items]                      
Contract revenue receivable if milestones achieved   $ 60.0